Editorial - EJNMMI radiopharmacy and chemistry.,EJNMMI Radiopharmacy and Chemistry

当前位置： X-MOL 学术 › EJNMMI Radiopharm. Chem. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Editorial - EJNMMI radiopharmacy and chemistry.
EJNMMI Radiopharmacy and Chemistry ( IF 4.4 ) Pub Date : 2016-03-21 , DOI: 10.1186/s41181-016-0006-4
Philip H Elsinga ₁

Affiliation

EJNMMI Radiopharmacy and Chemistry is a new journal within the EJNMMI family and is now ready to launch the first articles on-line. The aim of EJNMMI Radiopharmacy and Chemistry is to publish research in the field of new imaging and radionuclide based therapeutic agents that can be applied in nuclear medicine and molecular imaging.

This new journal provides an ideal platform for chemists, pharmacists and basic scientists to promote science, but also to exchange opinions and to provide updates on developments that have effect on availability of imaging agents for the clinic such as regulatory aspects.

EJNMMI Radiopharmacy and Chemistry reports original research articles, review papers, guidelines on application of imaging or radionuclide therapy agents, editorials, and letters to the editor. Research articles on novel radiochemistry, new radiopharmaceuticals including their first biological evaluation, molecular imaging agents including optical imaging, MRI, and hybrid probes, are the main focus of the journal. To translate imaging and radionuclide therapy agents to the clinic, legislative issues related to their production and safety can be presented as well in from of guidelines or position papers.

Radiopharmacy and radiochemistry are very essential for the development of nuclear medicine and molecular imaging and for its position in personalized medicine.

In this way, EJNMMI Radiopharmacy and Chemistry is very complementary to the other journals of the EJNMMI family, which focus mainly on (pre)clinical, technical and physical perspectives of nuclear medicine. With this new Journal we hope to establish a unique platform for our community.

Since the launch of EJNMMI Radiopharmacy and Chemistry in late October 2015 several manuscripts have been submitted, of which the first have now gone through the whole review process. So, we can now present the first number of accepted manuscripts. The Journal starts with a position paper developed by the EANM Radiopharmacy Committee on toxicity of radiopharmaceuticals, some new developments related to 68Ga-radiochemistry and an early preclinical studies. In addition some invited articles and original research articles are in the pipeline.

We are happy that a respectable number of scientist from all over the world have accepted the invitation to participate in the Editorial Board of EJNMMI Radiopharmacy and Chemistry. Their expertise covers a wide range of expertise in PET, SPECT and Molecular Imaging Radiopharmacy and Chemistry.

The members of the Editorial Board are: Mike Kilbourn (Ann Arbor, MI, USA), Jean Dasilva (Montreal, Canada), Jun Toyohara (Tokyo, Japan), Martin Behe (Villigen, Switzerland), Danielle Vugts (Amsterdam, The Netherlands), Clemens Decristoforo (Innsbruck, Austria), Ivan Penuelas (Pamplona, Spain), Bob Mach (Philadelphia, PN, USA), Klaus Kopka (Heidelberg, Germany), Jan Passchier (London, UK), Guy Bormans (Leuven, Belgium), Sally Schwarz (St. Louis, MO, USA), Sergio Todde (Monza, Italy), Ignasi Carrio (Barcelona, Spain), Angelika Bischof-Delaloye (Zürich, Switzerland), Ana Rey (Montevideo, Uruguay).

We hope you will enjoy reading the first articles in EJNMMI Radiopharmacy and Chemistry.

26 November 2018
The metadata in the HTML format of these original articles (Eppard et al., 2017; Decristoforo & Patt, 2017; Domnanich et al., 2017; Chan et al., 2017; Jovalekic et al., 2017; Zhang & Villalobos, 2017; Meckel et al., 2017; Li et al., 2017; Colin et al., 2017; Koziorowski et al., 2017; Ooms et al., 2017; Elsinga, 2017; Seemann et al., 2017; Müller et al., 2017; Luurtsema et al., 2017) were published with an incorrect cover date. The correct cover date is December 2016. This does not alter the text of the original articles.

Affiliations

University of Groningen, Groningen, Netherlands
Philip H. Elsinga

Authors

Philip H. ElsingaView author publications
You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Philip H. Elsinga.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Reprints and Permissions

Cite this article

Elsinga, P.H. Editorial - EJNMMI radiopharmacy and chemistry. EJNMMI radiopharm. chem. 1, 2 (2017). https://doi.org/10.1186/s41181-016-0006-4

Download citation

Received: 28 January 2016
Accepted: 11 February 2016
Published: 21 March 2016
DOI: https://doi.org/10.1186/s41181-016-0006-4

中文翻译：

社论-EJNMMI放射药学和化学。

《 EJNMMI放射药物与化学》是EJNMMI家族中的一本新期刊，现在准备在线发布第一篇文章。EJNMMI放射药物与化学的目的是发表可用于核医学和分子影像的新型影像学和基于放射性核素的治疗剂领域的研究。

这本新期刊为化学家，药剂师和基础科学家提供了一个理想的平台，以促进科学发展，还可以交换意见并提供对影响临床上成像剂可用性的研究进展（例如法规方面）的最新信息。

EJNMMI放射药物与化学专业杂志报道原始研究文章，评论论文，成像或放射性核素治疗剂应用指南，社论以及致编辑的信。有关新型放射化学，新型放射性药物（包括其首次生物学评估），分子成像剂（包括光学成像，MRI和混合探针）的研究文章是该期刊的主要重点。为了将成像和放射性核素治疗剂翻译到临床，可以从准则或立场文件中提出与生产和安全有关的法律问题。

放射药学和放射化学对于核医学和分子影像学的发展及其在个性化医学中的地位至关重要。

这样，EJNMMI放射药学和化学与EJNMMI家族的其他期刊非常互补，后者主要关注核医学的（临床前），技术和物理观点。我们希望借助这份新期刊来为我们的社区建立一个独特的平台。

自2015年10月下旬发布EJNMMI放射性药物和化学以来，已提交了几份手稿，其中第一份手稿现已完成整个审核过程。因此，我们现在可以介绍已接受手稿的第一个数量。该杂志以EANM放射性药物委员会针对放射性药物毒性，有关68Ga放射化学的一些新进展以及早期临床前研究开发的立场文件开始。此外，一些受邀的文章和原创研究文章正在准备中。

我们很高兴来自世界各地的众多科学家接受了邀请，参加了EJNMMI放射药物和化学编辑委员会。他们的专长涵盖PET，SPECT和分子成像放射药学与化学领域的广泛专长。

编辑委员会的成员是：Mike Kilbourn（美国密歇根州安阿伯市），Jean Dasilva（加拿大蒙特利尔），Jun Toyohara（日本东京），Martin Behe（瑞士维利根），Danielle Vugts（荷兰阿姆斯特丹）），Clemens Decristoforo（奥地利因斯布鲁克），Ivan Penuelas（西班牙潘普洛纳），Bob Mach（美国宾夕法尼亚州费城），Klaus Kopka（德国海德堡），Jan Passchier（英国伦敦），Guy Bormans（比利时鲁汶）），萨莉·施瓦茨（Sally Schwarz）（美国密苏里州圣路易斯），塞尔吉奥·托德（Sergio Todde）（意大利蒙扎），伊格纳西·卡里奥（Ignasi Carrio）（西班牙巴塞罗那），安吉丽卡·比绍夫-德拉洛伊（Angelika Bischof-Delaloye）（瑞士苏黎世），安娜·雷（Ana Rey）（乌拉圭蒙得维的亚）。

我们希望您会喜欢阅读EJNMMI放射药学和化学的第一篇文章。

2018年11月26日
这些原始文章的HTML格式的元数据（Eppard等人，2017; Decristoforo和Patt，2017; Domnanich等人，2017; Chan等人，2017; Jovalekic等人，2017; Zhang和Villalobos，2017 ; Meckel等人，2017; Li等人，2017; Colin等人，2017; Koziorowski等人，2017; Ooms等人，2017; Elsinga，2017; Seemann等人，2017;Müller等人（2017年； Luurtsema等人，2017年）的发布日期有误。正确的封面日期是2016年12月。这不会更改原始文章的文字。